BDX
Becton Dickinson
Health Care · Health Care Equipment · US

$149.43
Close 2025-09-30
✗ ETHICAL FAIL

NARROW MOAT

HIGH
Data Confidence: 100%
Full financial profile available

Market Cap
$41.2B
Trailing P/E
26.10
Forward P/E
11.10
Rev Growth
-10.6%
Profit Margin
5.1%
ROE
6.7%
Analyst Target
$183.29
Recommendation
BUY

About Becton Dickinson

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of haza

Opportunity Summary
Trading at $149 against a fair value of $270, a 45% discount. Fails ethical screen (Debt ratio). Ranks better than 70% of screened stocks.

Ethical Screen
Business Activity PASS
Debt Ratio (0.35%) FAIL
Cash Ratio (0.00%) PASS
Receivables Ratio (0.07%) PASS
Revenue Ratio (0.00%) PASS
Overall FAIL
Score Ethical: 10.0
Score Valuation: 88.0
Score Quality: 23.0
Score Combined: 40.2
Fair Value Est: $270.00 · Margin of Safety: +80.7% · Tier: AVOID

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership

Opportunity Scores
Valuation92.7
Quality8.7
Cash Flow100.0
Moat70.0
Balance Sheet77.4
Debt Purity0.0
Liquid Purity100.0
Rev Purity96.5
Compliance57.8
Tier: GOLD · Score: 76.9 · Rank: #119

Earnings History (Last 8 Quarters)
Date EPS Est. Reported EPS Surprise %
2026-08-06 3.13 Pending
2026-05-07 2.77 2.90 +4.5%
2026-02-09 0.26 1.34 +415.4%
2025-11-06 3.91 3.96 +1.1%
2025-08-07 3.40 3.68 +8.2%
2025-05-01 3.28 3.35 +2.1%
2025-02-05 2.99 3.43 +14.7%
2024-11-07 3.77 3.81 +1.1%

Quarterly Financials
Period Revenue Net Income EBITDA Gross Profit Op. Income EPS
2026-03-31 $4.7B -$311.0M $708.0M $2.2B $626.0M -1.11
2025-12-31 $5.3B $382.0M $1.2B $2.4B $662.0M 1.34
2025-09-30 $5.9B $493.0M $1.3B $2.8B $826.0M
2025-06-30 $5.5B $574.0M $1.6B $2.6B $979.0M 2.00
2025-03-31 $4.5B $308.0M $875.0M $1.9B $477.0M 1.07
2024-12-31 1.05

Insider Transactions
Date Name Role Shares Value
2026-05-07 ROQUE VITOR Chief Financial Officer 1,721
2026-04-27 FELD MICHAEL Officer 74 $11.2K
2026-03-26 FELD MICHAEL Officer 75 $11.8K
2026-03-16 MINNIX LANESHA General Counsel 7,492
2026-03-02 SPIKNER PAMELA L Officer 931
2026-03-02 ROQUE VITOR Chief Financial Officer 931
2026-02-26 FELD MICHAEL Officer 75 $13.6K
2026-02-18 SCOTT BERTRAM LEE Director 953 $174.0K
2026-01-27 RING TIMOTHY M Director 1,098
2026-01-27 WRIGHT JACQUELINE Director 1,098
Top Institutional Holders
Holder Shares Value % Held
Blackrock Inc. 26.2M $3.9B 0.1%
Vanguard Capital Management LLC 18.5M $2.7B 0.1%
Vanguard Portfolio Management LLC 15.3M $2.3B 0.1%
State Street Corporation 13.8M $2.0B 0.1%
First Eagle Investment Management, LLC 11.9M $1.8B 0.0%
Invesco Ltd. 10.2M $1.5B 0.0%
T. Rowe Price Investment Management, Inc. 9.7M $1.4B 0.0%
Massachusetts Financial Services Co. 9.1M $1.3B 0.0%
Geode Capital Management, LLC 7.1M $1.0B 0.0%
Wellington Management Group, LLP 6.6M $976.6M 0.0%

Analyst Recommendations
3 Months Ago
1
5
9
15 analysts

2 Months Ago
1
4
9
14 analysts

Last Month
2
4
9
15 analysts

Current
1
6
9
16 analysts

Strong Buy
Buy
Hold
Sell
Strong Sell

Additional Fundamentals
Enterprise Value
$57.1B
Price/Book
1.69
Beta
0.285
Analysts
14
Total Revenue (TTM)
$22.2B
Total Debt
$17.3B
Dividend Yield
281.0%
Rec. Mean
2.19
Short Ratio
2.35
Short % Float
0.0%
Employees
60,000

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite

Trade Consideration

The Opportunity
Score 40.2 (P44 — top 55.6% of scored tickers). Narrow Moat. Ethical FAIL. 14 analysts at Buy.
Price: $149.43 | Target: $183.29 (+23%) | Fair Value: $270.00 (+81%)

Score
40

Moat
NARROW

Conviction
Standard

Upside
+23%

The Fundamentals
Revenue Growth-10.6%
Profit Margin0.0%
ROE6.7%
Forward P/E11.1
Market Cap$41.2B

Earnings Track Record
Date Estimate Reported Surprise
2026-08-06 $3.13 Pending
2026-05-07 $2.77 $2.90 +4.5%
2026-02-09 $0.26 $1.34 +415.4%
2025-11-06 $3.91 $3.96 +1.1%
2025-08-07 $3.40 $3.68 +8.2%
2025-05-01 $3.28 $3.35 +2.1%
Position Sizing Scenarios
Stop: $127.02 (-15%) | Entry: $149.43
Shares Cost Profit to Target R:R
To Consensus ($183.29, 14 analysts)
10 $1,494.30 +$338.60 (23%) 1.5R
50 $7,471.50 +$1,693.00 (23%) 1.5R
100 $14,943.00 +$3,386.00 (23%) 1.5R
To Fair Value ($270.00)
10 $1,494.30 +$1,205.70 (81%) 5.4R
50 $7,471.50 +$6,028.50 (81%) 5.4R
100 $14,943.00 +$12,057.00 (81%) 5.4R
Risk Factors
  • No elevated risk flags in current data

The Verdict
Becton Dickinson holds a narrow competitive moat and trades at a 80.7% discount to fair value.

Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

C
Quant Score
45.2
Risk Grade
LOW_RISK
Layers
8
Quality: CONSISTENT_BEATER,STRONG_EARNINGS_DRIFT

Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-2.1%
worst expected daily loss, 19 in 20 days
CVaR 95%
-3.8%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
-0.31
above 1.0 is good
Max Drawdown
-33.4%
Worst Day

Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
90
Liquidity Grade
HIGHLY LIQUID

Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal

Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
DEATH_CROSS
Bollinger Position
UPPER_HALF
Beta
Relative Volume
0.9x
Short Interest

Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone

Piotroski F-Score

Earnings Beat Rate
100.0%
Earnings Consistency

Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
Ticker Correlation
XLV 0.531
STE 0.477
MDT 0.461
TMO 0.452
ASH 0.447
Inverse Correlated
Ticker Correlation
QFBQ.QA -0.185
LPTVQ -0.171
OXLCO -0.137
9022.T -0.136
JAZEERA.KW -0.134

Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Tuesday
Worst Day
Thursday
Best Month
Jan
Worst Month
May
Fri-Mon Effect
0.22585886655981155

Earnings Drift

After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.

Avg Drift After Beat
+0.8%
Beat Drift Positive %
71.4%
Consistency

Momentum Rankings

How does this ticker’s recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
-2.9%
3M Return
-18.5%
6M Return
+0.3%
12M Return
+11.6%
Momentum Rank
#3401
Momentum Signal
DOWN

Related Tickers

Similar in Healthcare

INCY — Incyte CRMD — CorMedix Inc. ✓ UHS — Universal Health Services ✓ FENC — Fennec Pharmaceuticals Inc. ✓ REGN — Regeneron Pharmaceuticals ✓

Also in TE500

NEM — Newmont ✓ NU — Nu Holdings Ltd. PTC — PTC Inc. ✓ SBNY — Signature Bank EXE — Expand Energy ✓
Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry Indicators Options Calendar Composites Boycott Tracker Convergence Screener Fed Tracker Explore All Is It Halal? Earnings Calendar Dividend Screener Country Guides Glossary Join Free →

Get our weekly market brief free.